Advertisement
Advertisement
U.S. markets open in 59 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
89.52+1.03 (+1.16%)
At close: 04:03PM EDT
90.39 +0.87 (+0.97%)
Pre-Market: 08:30AM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • G
    GONYON
    I don't think that MRK has another 10% in gains in it. Looks pretty bad here. I actually found (http://Achieverspot.tech) the other day and their stocks are way better...
  • j
    james
    $SLS conversation
    Speaking of the $MRK expanded partnership and license, don’t forget $BMY. Mesohope article: ‘..results of this [gp-s opdivo] single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks. Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.’

    https://www.mskcc.org/cancer-care/clinical-trials/17-654
    Dr. Zauderer The Mesothelioma Dept chair at Memorial Sloan Kettering is investigating Gps combined w Opdivo for refractory patients, who have exhausted all options. Gps + Opdivo safety has been established, with no grade 3/4 and very few side effects beyond standard vaccination related symptoms.
    No brainer BMY is interested in combining Opdivo a CP Inhibitor, that removes the immune systems' brakes with Gps, the most effective t cell generation agent for 20 WT1 cancers. Gps has demonstrated broad spectrum epitope spread with B Cell cd3 Memory T cells, the hall mark of an effective long term, durable survival extension, in every trial.

    Therapy benefits of 10.5 months / 45.5 weeks vs 22* currently. Gps is already extending os rates nearly 5 months for sicker patients than what Opdivo + Yervoy was approved for in healthier patients.
    - Opdivo Yervoy recently Fda approved after extending survival 4 months for these patients in the front line setting.

    https://www.fiercepharma.com/pharma/wclc-bms-opdivo-yervoy-duo-slashes-mesothelioma-death-risk-by-26
    ". helping them live a median four months longer than those in the study’s chemo arm."

    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines.

    Saturday at the World Conference on Lung Cancer’s virtual presidential symposium, Bristol Myers unveiled phase 3 data showing the pair decreased the risk of death among previously untreated mesothelioma patients by 26%, helping them live a median four months longer than those in the study’s chemo arm.
    Bullish
  • j
    james
    $SLS conversation
    Speaking of the $MRK expanded partnership and license, don’t forget $BMY. Mesohope article: ‘..results of this [gp-s opdivo] single-center trial included a median overall survival of 10.5 months from the time the earlier treatment was stopped. By comparison, patients with relapsed or refractory mesothelioma typically have an estimated overall survival of just 20-24 weeks. Six of the eight patients in this latest trial arrived in stage 3 or 4. The median survival time of 10.5 months is expected to improve as the trial progresses. Half of the patients were alive when results were released.’

    https://www.mskcc.org/cancer-care/clinical-trials/17-654
    Dr. Zauderer The Mesothelioma Dept chair at Memorial Sloan Kettering is investigating Gps combined w Opdivo for refractory patients, who have exhausted all options. Gps + Opdivo safety has been established, with no grade 3/4 and very few side effects beyond standard vaccination related symptoms.
    No brainer BMY is interested in combining Opdivo a CP Inhibitor, that removes the immune systems' brakes with Gps, the most effective t cell generation agent for 20 WT1 cancers. Gps has demonstrated broad spectrum epitope spread with B Cell cd3 Memory T cells, the hall mark of an effective long term, durable survival extension, in every trial.

    Therapy benefits of 10.5 months / 45.5 weeks vs 22* currently. Gps is already extending os rates nearly 5 months for sicker patients than what Opdivo + Yervoy was approved for in healthier patients.
    - Opdivo Yervoy recently Fda approved after extending survival 4 months for these patients in the front line setting.

    https://www.fiercepharma.com/pharma/wclc-bms-opdivo-yervoy-duo-slashes-mesothelioma-death-risk-by-26
    ". helping them live a median four months longer than those in the study’s chemo arm."

    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines.

    Saturday at the World Conference on Lung Cancer’s virtual presidential symposium, Bristol Myers unveiled phase 3 data showing the pair decreased the risk of death among previously untreated mesothelioma patients by 26%, helping them live a median four months longer than those in the study’s chemo arm.
    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines. | It’s been a big year for Bristol-Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines
    It’s been a big year for Bristol Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines. | It’s been a big year for Bristol-Myers Squibb’s Opdivo-Yervoy combo in lung cancer, but the duo isn’t done making headlines
    www.fiercepharma.com
  • C
    Cured
    $SLS conversation
    Simple investment thesis: Super low float, cash for almost 2 years, more coming + 3 Trial studies to report in the next quarter $MRK $BMY CDK9, along with an AML FDA Green light in Q1/2, by all accounts worth billions.

    Upcoming News:
    Now that the REGAL Phase 3 is in the Home stretch, a mere ReIteration of the Phase 3 Results Timeline will launch this baby bio.

    Seriously, is a quarter or 2 a long time to wait for a 2,500% Return on an Investment?

    MD Andersons Leukemia depart chairman running the Ph 3, who sees all the open label trial results, requesting Expanded Access, confirms 2 things; 1. Gps is doing what it has done in every trial, cure patients and extend survival well beyond existing treatment, and 2. Guarantees Immediate off-label prescription and ultimate FDA Approved Expanded label to Cr1 / PostASCT which is 5x the $200M Cr2 initial niche revenue projected by CF.

    95% of drugs w EAP’s get FDA approved.

    Hello!
    Bullish
  • T
    TrufflesDrive
    What time is the earnings report on Thursday ?
  • S
    SamIAm
    It was a very good report. Even Keytruda sales surpassed They lowered the top range of guidance by a penny from previous estimates but sheesh market is acting like it was a miss! Unbelievable!
  • R
    Robert
    When was the last time we went green?
  • M
    Michael
    Going down when it should have went to $100 on the earnings report.
  • B
    Brent
    Barclays raises to over $100 joining others with a $100+ pt. Buy.
  • C
    Cured
    $SLS conversation
    Illustrates how over shorted $SLS is right now $Blte Phase 2 8 of 13 patients respond; Compare that to the $mrk Phase 2 trial Combining Gps with Keytruda, Final Data now due, with an overall survival duration that will far surpass all other ovarian cancer treatments. Or the MSK Mesothelioma data that again is better than all other treatments - Not to mention the FDA Green Light is a quarter or two away with the results of Phase 3 AML Trial.
    https://www.biopharmadive.com/news/belite-bio-stargardt-dry-AMD-drugmaker-biotech-best-performing-ipo/628589/
    Belite's shares have risen nearly 500% from their IPO price at a time when many other newly public biotech companies are struggling to hold their value.
    Belite's shares have risen nearly 500% from their IPO price at a time when many other newly public biotech companies are struggling to hold their value.
    www.biopharmadive.com
  • W
    WILLIAM
    I hope MRK doesn't have to pay $200/ share for SGEN.
  • B
    Brent
    Sensing we go green by day's end.
  • E
    EnjoyinCVM
    Y’all have a 230 market cap, you think you can afford a working cancer treatment buyout? Try CVM!!

    They’re only worth $200m 😂
    Bullish
  • J
    JsR
    Layoffs coming.
  • B
    Brent
    Strong report. Over $100 soon enough.
  • R
    Ronald
    MRK should buy AGEN and than, watch the $$$ go 100+
  • M
    Martin
    Why down?
    Bearish
  • J
    JsR
    Merck is fully valued at $93/share.
    Neutral
  • P
    Pg
    why is down?? just cause of the bill?
Advertisement
Advertisement